Management of leptomeningeal malignancy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 7, 2005, Pages 1115-1125

  Pentheroudakis, George ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Leptomeningeal; Malignancy; Management

Indexed keywords

ANTIEMETIC AGENT; ANTIPYRETIC AGENT; BETA 2 MICROGLOBULIN; CARCINOEMBRYONIC ANTIGEN; CYTARABINE; DEXAMETHASONE; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; LACTATE DEHYDROGENASE; MAFOSFAMIDE; METHOTREXATE; MYELIN BASIC PROTEIN; RITUXIMAB; STEROID; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; VASCULOTROPIN;

ARACHNOIDITIS; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMATOUS MENINGITIS; CEREBELLUM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DERMATITIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; FEVER; HEADACHE; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; LEPTOMENINX; LEUKOENCEPHALOPATHY; LIFE EXPECTANCY; LIVER TOXICITY; MENINGEAL METASTASIS; MENINGISM; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPINAL CORD DISEASE; VOMITING;

ADENOCARCINOMA; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ARACHNOID CYSTS; CARCINOMA; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; DELAYED-ACTION PREPARATIONS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; LEUKEMIA; LYMPHOMA; MENINGEAL NEOPLASMS; METHOTREXATE; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; THIOTEPA; TOPOTECAN;

EID: 21844480381     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.7.1115     Document Type: Review

References (43)

1. EBERTH CJ: Zur entwicklung des epitheliomas dur pia under der lungs. Virchow's Arch. (1870) 49:51-63.
2. GROSSMAN SA, KRABAK US. Leptomeningeal carcinomatosis. Cancer Treat. Rev. (1999) 25:103-109.
3. HILDEBRAND J, AOUN M: Chronic meningitis: still a diagnostic challenge. J. Neurol. (2003) 250:653-660.
4. FREEMAN AI, BOYETT JM, GLICKSMAN AS et al.: Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten year follow-up. Med. Pediatr. Oncol. (1997) 28:98-107.
5. HERMAN TS, HAMMOND N, JONES SE et al.: Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group Experience. Cancer (1979) 43:390-397.
6. WASSERSTROM WR, GLASS JP, POSNER JB: Diagnosis and treatment of leptomeningeal metastases from solid tumours: experience with 90 patients. Cancer (1982) 49:759-772.
7. VAN DER REE TC, DIPPEL DW, AVEZAAT Q et al.: Leptomeningeal metastasis after surgical resection of brain metastases. J. Neurol. Neurosurg. Psychiatry (1999) 66:225-227.
8. CRIVELARI D, PAGANI O, VERONESI A et al.: High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann. Oncol. (2001) 12:353-356.
9. BENDELL JC, DOMCHEK SM, BURNSTEIN HJ et al.: Central nervous system metastases in women who receive tratuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 97:2972-2977.
10. KOKKORIS CP: Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer (1983) 51:154-160.
11. DIMOPOULOS A: Leptomeningeal metastases. Curr. Neurol. Neurosci. Rep. (2004) 4(3):196-204.
12. PAVLIDIS N: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann. Oncol. (2004) 15(Suppl. 4):285-291.
13. CHAMBERLAIN MC, KORMANIK PA, GLANTZ MJ: A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro. Oncol. (2001) 3:42-45.
14. COLLIE DA, BRUSH JP, LAMMIE GA et al.: Imaging features of leptomeningeal metastases. Clin. Radiol. (1999) 54:765-771.
15. HUSTO HO, AUR RJ, VERZOSA MS et al.: Prevention of central nervous system leukemia by irradiation. Cancer (1973) 32:585-597.
16. SAUSE WT, CROWLEY J, EYRE HJ et al.: Whole brain irradiation and intrathecal merhotrexate in the treatment of solid tumour leptomeningeal metastases-a Southwest Oncology Group study. J. Neuro-Oncol. (1988) 6:107-112.
17. BOOGERD W, VAN DEN BENT MJ, KOEHLER PJ et al.: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. J. Cancer (2004) 40:2726-2733.
18. BLEYER WA: Intrathecal depot cytarabine therapy: a welcome additon to a limited armamentarium. Clin. Cancer Res. (1999) 5:3349-3351.
19. TSUCHIYA J, MOTEKI M, SHIMANO S et al.: Proliferation kinetics of the leukemic cells in meningeal leukemia. Cancer (1978) 42:1255-1262.
20. LISHNER M, PERRIN RG, FELD R et al.: Complications associated with Ommaya reservoirs in patients with cancer. Arch. Int. Med. (1990) 150:173-176.
21. ZIMM S, COLLINS JM, MISER J et al.: 1-β-D-Arabinofuranosylcytosine cerebrospinal fluid kinetics. Clin. Pharmacol. Ther. (1984) 35:826-830.
22. BLEYER WA: Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat. Rev. (1977) 4:87-101.
23. BERG SL, CHAMBERLAIN MC: Systemic chemotherapy, intrathecal chemotherapy and symptom management in the treatment of leptomeningeal metastasis. Curr. Oncol. Rep. (2003) 5:29-40.
24. CHAMBERLAIN MC, KORMANIK P: Carcinomatous meningitis secondary to non small cell lung cancer: combined modality therapy. Arch. Neurol. (1998) 55:506-512.
25. KIM DY, LEE KW, YUN T et al.: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumour: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn. J. Clin. Oncol. (2003) 33(12):608-612.
26. CHAMBERLAIN MC, KORMANIK PA: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J. Neurosurg. (1997) 87:694-699.
27. PFEFFER MR, WYGODA M, SIEGAL T: Leptomeningeal metastases-treatment results in 98 consecutive patients. Israel J. Med. Sci. (1988) 24:611-618.
28. SIEGAL T, SANDBANK U, GABRIZON A et al.: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis: a morphologic and adriamycin-penetration study. J. Neuro-Oncol. (1987) 4:233-242.
29. TETEF ML, MARGOLIN KA, DOROSHOW JH et al.: Pharmacokinetics and roxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother. Pharmacol. (2000) 46:19-22.
30. CHAMBERLAIN MC, KORMANIK P, GLANTZ M: Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol. Rep. (1998) 5:521-523.
31. GLANTZ MJ, COLE BF, RECHT L et al.: High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol. (1998) 16:1561-1567.
32. FRICK J, RITCH PS, HANSEN RN, ANDERSON T: Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J. Clin. Oncol. (1984) 2:365-368.
33. BLEYER W: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat. Rep. (1981) 65(Suppl. 1):89-98.
34. MURRY DJ, BLANEY SM: Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. (2000) 34:1173-1178.
35. GLANTZ MJ, LAFOLLETTE S, JAECKLE KA et al.: Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. (1999) 17:3110-3116.
36. GLANTZ MJ, JAECKLE KA, CHAMBERLAIN MC et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine to intrathecal methotrexate in patients with neoplastic meningitis from solid tumours. Clin. Cancer Res. (1999) 5:3394-3402.
37. BLANEY S, COLE D, BALIS E et al.: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in human primates. Cancer Res. (1993) 53:725-727.
38. BLANEY S, HEIDEMAN R, BERG S et al.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol. (2003) 21:143-147.
39. SCHULZ H, PELS H, SCHMIDT-WOLF I, ZEELEN U, GERMING U, ENGERT A: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) 89:753-754.
40. LAUFMAN LR, FORSTHOEFEL KF: Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin. Breast Cancer (2001) 2:235.
41. FRIEDMAN HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin. Oncol. (2000) 27(Suppl. 6)35-40.
42. SIEGAL T, LOSSOS A, PFEFFER MR: Leptomeningeal metastasis: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology (1994) 44:1463-1469.
43. BOOGERD W, HART AA, VAN DER SANDE JJ, ENGELSMAN E: Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer (1991) 67:1685-1695.